Updates are available Correction dated 2024-10-30

Article History

Received: 6 March 2024

Accepted: 20 September 2024

First Online: 4 October 2024

Change Date: 30 October 2024

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s41467-024-53775-4

Competing interests

: C.L.T.: Roche, Seattle Genetics, Rakuten, Nanobiotix, MSD, BMS, Merck Serono, AstraZeneca, GlaxoSmithKline, Novartis, Celgene, Exscientia, ALX Oncology, Seattle Genetics. M.K.: Roche, AstraZeneca. Pernelle Lavaud: Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from BMS, Astra Zeneca, Sanofi, Astellas; Support for attending meetings and/or travail from Daichi, Ipsen, Astellas, Sanofi, Jannssen, Pfizer; Advisory board from Daichi. L.L.: Hospitalities, Travel, advice board, research grant last 5 years with: Abbott; Adept Field Solutions; Amgen; AstraZeneca; Beckman Coulter; Bayer Boeringer; BMS; Icomed; Illumina, Genomic Health; Guardant health; Lilly; Medimmune; Myriad; Novartis; Pfizer; QualWorld1; Roche; Siemens Healthineer; Taiho Oncology, Thermofisher Sc; VelaDx. E.R.: Travel, advice board, research grant: AstraZeneca, Roche, BMS, GSK, and Clovis. L.F.: Research funding from Debiopharm, Incyte, Relay Therapeutics and Nuvalent and Non financial support from Illumina Inc and Guardant Health. F.F.: no disclosures. Benjamin Besse: grants from 4D Pharma, AbbVie, Amgen, AstraZeneca, BeiGene, Blueprint Medicines, Celgene, Cergentis, Chugai Pharmaceutical, Da Voltera, Daiichi Sankyo, Eli Lilly, Ellipse Pharma, Eisai, F-Star, Genmab, Genzyme Corporation, GSK, Hedera Dx, Inivata, Ipsen, Janssen, MSD, Onxeo, OSE Immunotherapeutics, Pfizer, Pharmamar, Roche/Genentech, Sanofi, Socar Research, Taiho Oncology, Takeda, Tolero Pharmaceuticals, and Turning Point Therapeutics during the conduct of the study. C.M.: Consultant/Advisory fees from Amgen, Astellas, Astra Zeneca, Bayer, BeiGene, BMS, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Lilly, MedImmune, MSD, Novartis, Pfizer, Roche, Sanofi, Orion. Principal/sub-Investigator of Clinical Trials for Abbvie, Aduro, Agios, Amgen, Argen-x, Astex, AstraZeneca, Aveo pharmaceuticals, Bayer, Beigene, Blueprint, BMS, Boeringer Ingelheim, Celgene, Chugai, Clovis, Daiichi Sankyo, Debiopharm, Eisai, Eos, Exelixis, Forma, Gamamabs, Genentech, Gortec, GSK, H3 biomedecine, Incyte, Innate Pharma, Janssen, Kura Oncology, Kyowa, Lilly, Loxo, Lysarc, Lytix Biopharma, Medimmune, Menarini, Merus, MSD, Nanobiotix, Nektar Therapeutics, Novartis, Octimet, Oncoethix, Oncopeptides AB, Orion, Pfizer, Pharmamar, Pierre Fabre, Roche, Sanofi, Servier, Sierra Oncology, Taiho, Takeda, Tesaro, Xencor. F.A.: grants from Roche, Lilly, Novartis, Pfizer, Daiichi Sankyo, and AstraZeneca outside the submitted work. Y.L.: personal fees, and non-financial support from Sanofi, Janssen, Astellas, Seattle Genetics, Gilead, AstraZeneca, BMS, MSD, Pfizer, Merck KGaA, Pfizer, and Tahio; grants, grants from Celsius, Sanofi, Roche, MSD. The remaining authors declare no competing interests.